Previous Close | 24.05 |
Open | 24.20 |
Bid | 24.52 x 300 |
Ask | 24.70 x 300 |
Day's Range | 23.70 - 25.61 |
52 Week Range | 4.82 - 26.24 |
Volume | |
Avg. Volume | 1,220,221 |
Market Cap | 1.967B |
Beta (5Y Monthly) | 0.71 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for RNA
Michael Maclean, Chief Financial Officer of Avidity Biosciences Inc (NASDAQ:RNA), sold 40,000 shares of the company on March 13, 2024, according to a recent SEC filing.
Top-notch biotech stock Avidity tumbled Monday despite unveiling "positive" midstage test results for its muscular dystrophy treatment.
Avidity Biosciences ( NASDAQ:RNA ) Full Year 2023 Results Key Financial Results Net loss: US$212.2m (loss widened by...